Astellas Pharma extends tender offer for OSI Pharmaceuticals

NewsGuard 100/100 Score
Apr 23 2010

Astellas Pharma Inc. (TSE: 4503) announced today that it has extended its all-cash tender offer for $52 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) to 5:00 p.m. New York City time on Monday, May 17, 2010, unless further extended.  The tender offer was previously set to expire at 12:00 midnight New York City time on Friday, April 23, 2010.

As of 4:00 p.m. New York City time on Thursday, April 22 2010, 42,283 shares of OSI had been tendered in and not withdrawn from the tender offer.

Citigroup is acting as exclusive financial advisor to Astellas and Morrison & Foerster LLP is acting as legal counsel.

SOURCE Astellas Pharma US, Inc.

Posted in:

Tags: , , , , ,

Comments (0)

Suggested Reading

New urine-based test improves identification of high-grade prostate cancer
SickKids study offers new path for pediatric rare disease clinical trials
Lancet Commission predicts sharp increase in global prostate cancer cases
Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms
LabVantage celebrates customer success with record number of software deployments in FY 2024
Common HIV drugs linked to reduced Alzheimer's disease risk
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status